The first patient has been dosed in a Phase 1 clinical trial of KB407, Krystal Biotech’s investigational gene therapy…
Articles by Andrea Lobo, PhD
The presence of intestinal metabolites called bile acids in the airways of 1-year-old children genetically diagnosed with cystic fibrosis…
Kaftrio (elexacaftor, tezacaftor, and ivacaftor) safely and effectively eases structural lung damage and improves lung function and the quality of…
Antibiotic resistance is high among cystic fibrosis (CF) patients infected with Staphylococcus aureus (S. aureus), according to a recent…
Reducing the dose of Kaftrio (elexacaftor, tezacaftor, and ivacaftor) should be considered for cystic fibrosis (CF) patients who…
The Cystic Fibrosis Foundation is funding up to $3.9 million to TB Alliance to conduct preclinical studies of…
First Wave BioPharma has completed patient screening for the Phase 2 SPAN clinical trial of a new formulation of…
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to…
SPRIM Global Investments (SGI) has committed $4.5 million to initiate Spexis’ Phase 3 COPILOT clinical trial to test the…
The Cystic Fibrosis Foundation (CFF) is investing up to $15.5 million in Anagram Therapeutics to conduct early-stage trials…